Abstract
Primary graft failure (pGF) is associated with considerable morbidity and mortality. Salvage hematopoietic SCT (HSCT) can rescue pGF patients; however, the optimal preconditioning regimen and stem cell source are yet to be determined, particularly in children. In this study, we retrospectively analyzed 102 pediatric patients who received salvage allogeneic HSCT for pGF. Salvage HSCT from matched or one-Ag-mismatched related donors (rMM01) provided superior OS compared with that from two- or three-Ags-mismatched related donors (rMM23) or cord blood transplantation (CBT). CBT showed a trend toward a slightly lower engraftment rate and late engraftment achievement compared with rMM23; however, the OS rate was similar between the two groups (47.6±7.7% for rMM23 and 45.7±8.6% for CBT, at 1 year after salvage HSCT). Multivariate analysis showed that preconditioning regimens with fludarabine or irradiation were associated with a higher engraftment rate and those with alkylating agents were associated with better OS. In conclusion, our results showed that rMM01 was the most suitable donor for salvage HSCT for pediatric pGF, and that CBT was an equally important option compared with rMM23 for patients without rMM01.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hansen JA, Gooley TA, Martin PJ, Appelbaum F, Chauncey TR, Clift RA et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 1998; 338: 962–968.
Shaw BE, Russell NH, Devereux S, Das-Gupta E, Mackinnon S, Madrigal JA et al. The impact of donor factors on primary non-engraftment in recipients of reduced intensity conditioned transplants from unrelated donors. Haematologica 2005; 90: 1562–1569.
Baron F, Sandmaier BM . Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Leukemia 2006; 20: 1690–1700.
Clift RA, Buckner CD, Thomas ED, Bensinger WI, Bowden R, Bryant E et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994; 84: 2036–2043.
McCann SR, Bacigalupo A, Gluckman E, Hinterberger W, Hows J, Ljungman P et al. Graft rejection and second bone marrow transplants for acquired aplastic anaemia: a report from the Aplastic Anaemia Working Party of the European Bone Marrow Transplant Group. Bone Marrow Transplant 1994; 13: 233–237.
Anasetti C, Amos D, Beatty PG, Appelbaum FR, Bensinger W, Buckner CD et al. Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 1989; 320: 197–204.
Horan J, Wang T, Haagenson M, Spellman SR, Dehn J, Eapen M et al. Evaluation of HLA matching in unrelated hematopoietic stem cell transplantation for nonmalignant disorders. Blood 2012; 120: 2918–2924.
Spellman S, Bray R, Rosen-Bronson S, Haagenson M, Klein J, Flesch S et al. The detection of donor-directed, HLA-specific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure. Blood 2010; 115: 2704–2708.
Guardiola P, Kuentz M, Garban F, Blaise D, Reiffers J, Attal M et al. Second early allogeneic stem cell transplantations for graft failure in acute leukaemia, chronic myeloid leukaemia and aplastic anaemia. French Society of Bone Marrow Transplantation. Br J Haematol 2000; 111: 292–302.
Kanda J, Horwitz ME, Long GD, Gasparetto C, Sullivan KM, Chute JP et al. Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2012; 47: 700–705.
Min CK, Kim DW, Lee JW, Min WS, Kim CC . Additional stem cell therapy for graft failure after allogeneic bone marrow transplantation. Acta Haematol 2000; 104: 185–192.
Schriber J, Agovi MA, Ho V, Ballen KK, Bacigalupo A, Lazarus HM et al. Second unrelated donor hematopoietic cell transplantation for primary graft failure. Biol Blood Marrow Transplant 2010; 16: 1099–1106.
Waki F, Masuoka K, Fukuda T, Kanda Y, Nakamae M, Yakushijin K et al. Feasibility of reduced-intensity cord blood transplantation as salvage therapy for graft failure: results of a nationwide survey of adult patients. Biol Blood Marrow Transplant 2011; 17: 841–851.
Wolff SN . Second hematopoietic stem cell transplantation for the treatment of graft failure, graft rejection or relapse after allogeneic transplantation. Bone Marrow Transplant 2002; 29: 545–552.
Jabbour E, Rondon G, Anderlini P, Giralt SA, Couriel DR, Champlin RE et al. Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation. Bone Marrow Transplant 2007; 40: 431–435.
Gyurkocza B, Cao TM, Storb RF, Lange T, Leisenring W, Franke GN et al. Salvage allogeneic hematopoietic cell transplantation with fludarabine and low-dose total body irradiation after rejection of first allografts. Biol Blood Marrow Transplant 2009; 15: 1314–1322.
Yoshihara S, Ikegame K, Taniguchi K, Kaida K, Kim EH, Nakata J et al. Salvage haploidentical transplantation for graft failure using reduced-intensity conditioning. Bone Marrow Transplant 2012; 47: 369–373.
Sumi M, Shimizu I, Sato K, Ueki T, Akahane D, Ueno M et al. Graft failure in cord blood transplantation successfully treated with short-term reduced-intensity conditioning regimen and second allogeneic transplantation. Int J Hematol 2010; 92: 744–750.
Fuji S, Nakamura F, Hatanaka K, Taniguchi S, Sato M, Mori SI et al. Peripheral blood as a preferable source of stem cells for salvage transplantation in patients with graft failure after cord blood transplantation: A retrospective analysis of the registry data of the Japanese Society for Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 2012; 18: 1407–1414.
Lang P, Mueller I, Greil J, Bader P, Schumm M, Pfeiffer M et al. Retransplantation with stem cells from mismatched related donors after graft rejection in pediatric patients. Blood Cells Mol Dis 2008; 40: 33–39.
Dvorak CC, Gilman AL, Horn B, Cowan MJ . Primary graft failure after umbilical cord blood transplant rescued by parental haplocompatible stem cell transplantation. J Pediatr Hematol Oncol 2009; 31: 300–303.
Liu H, Wang X, Geng L, Tang B, Tong J, Yao W et al. Successful second transplantation with non-myeloablative conditioning using haploidentical donors for young patients after graft failure following double umbilical cord cell transplantation. Pediatr Transplant 2010; 14: 465–470.
Atsuta Y, Suzuki R, Yoshimi A, Gondo H, Tanaka J, Hiraoka A et al. Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP system. Int J Hematol 2007; 86: 269–274.
Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009; 15: 1628–1633.
Gaziev D, Polchi P, Lucarelli G, Galimberti M, Sodani P, Angelucci E et al. Second marrow transplants for graft failure in patients with thalassemia. Bone Marrow Transplant 1999; 24: 1299–1306.
Larocca A, Piaggio G, Podesta M, Pitto A, Bruno B, Di Grazia C et al. Boost of CD34+-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation. Haematologica 2006; 91: 935–940.
Remberger M, Ringden O, Ljungman P, Hagglund H, Winiarski J, Lonnqvist B et al. Booster marrow or blood cells for graft failure after allogeneic bone marrow transplantation. Bone Marrow Transplant 1998; 22: 73–78.
Deeg HJ, Amylon ID, Harris RE, Collins R, Beatty PG, Feig S et al. Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation. Biol Blood Marrow Transplant 2001; 7: 208–215.
Deeg HJ, O'Donnell M, Tolar J, Agarwal R, Harris RE, Feig SA et al. Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood 2006; 108: 1485–1491.
Acknowledgements
We thank all the clinicians and leaders of hospitals and centers who provided precise data via a registry of the Japan Society for Hematopoietic Cell Transplantation (JSHCT). Script kindly given by Dr Yoshinobu Kanda was used for data manipulation.
Author contributions
MK, KM, RS and TF designed the research. HY, MI, HK, JI, K Koh, YH, HT, AS, AK, HS, K Kawa and K Kato collected the data. MK analyzed the data, and MK and TF wrote the manuscript. All the authors discussed the results and commented on the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Kato, M., Matsumoto, K., Suzuki, R. et al. Salvage allogeneic hematopoietic SCT for primary graft failure in children. Bone Marrow Transplant 48, 1173–1178 (2013). https://doi.org/10.1038/bmt.2013.36
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2013.36
Keywords
This article is cited by
-
Outcomes of salvage haploidentical transplantation using posttransplant cyclophosphamide for graft failure following allogeneic hematopoietic stem cell transplantation
International Journal of Hematology (2022)
-
Comparison of immunosuppressant regimens in salvage cord blood transplantation for graft failure after allogeneic hematopoietic stem cell transplantation
Bone Marrow Transplantation (2021)
-
Prognostic factors in salvage transplantation for graft failure following allogeneic hematopoietic stem cell transplantation
Bone Marrow Transplantation (2021)
-
Comparison of the outcomes after haploidentical and cord blood salvage transplantations for graft failure following allogeneic hematopoietic stem cell transplantation
Bone Marrow Transplantation (2020)
-
Clinical course of autologous recovery with chromosomal abnormalities after allogeneic hematopoietic stem cell transplantation
Bone Marrow Transplantation (2020)